0001209191-21-030096.txt : 20210504
0001209191-21-030096.hdr.sgml : 20210504
20210504192212
ACCESSION NUMBER: 0001209191-21-030096
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20210503
FILED AS OF DATE: 20210504
DATE AS OF CHANGE: 20210504
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Kung Winston
CENTRAL INDEX KEY: 0001666963
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39539
FILM NUMBER: 21890525
MAIL ADDRESS:
STREET 1: C/O CELGENE CORPORATION
STREET 2: 86 MORRIS AVENUE
CITY: SUMMIT
STATE: NJ
ZIP: 07901
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: PMV Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001699382
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 463218129
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 8 CLARKE DRIVE
CITY: CRANBURY
STATE: NJ
ZIP: 08512
BUSINESS PHONE: (609) 642-6664
MAIL ADDRESS:
STREET 1: 8 CLARKE DRIVE
CITY: CRANBURY
STATE: NJ
ZIP: 08512
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-05-03
0
0001699382
PMV Pharmaceuticals, Inc.
PMVP
0001666963
Kung Winston
C/O PMV PHARMACEUTICALS, INC.
8 CLARKE DRIVE, SUITE 3
CRANBURY
NJ
08512
0
1
0
0
COO, CFO
Common Stock
2021-05-03
4
M
0
4500
3.22
A
6100
D
Common Stock
2021-05-03
4
S
0
4500
33.75
D
1600
D
Stock Option (right to buy)
3.22
2021-05-03
4
M
0
4500
0.00
D
2028-02-21
Common Stock
4500
232534
D
Stock Option (right to buy)
3.22
2028-02-21
Common Stock
237412
237412
I
See footnote
The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 29, 2020.
The option is subject to an early exercise provision and is immediately exercisable. The underlying shares vest in accordance with the terms of the option grant.
All of the shares subject to the option are vested and immediately exercisable.
The shares are held of record by the Winston Kung Irrevocable Family Trust for the benefit of the Reporting Person's immediate family.
Exhibit 24 - Power of Attorney
/s/ Robert Ticktin, by power of attorney
2021-05-04
EX-24.4_982555
2
poa.txt
POA DOCUMENT
POWER OF ATTORNEY
The undersigned, as a Section 16 reporting person of PMV Pharmaceuticals, Inc.
(the "Company"), hereby constitutes and appoints David H. Mack, Ph.D. and Robert
Ticktin, and each of them, as the undersigned's true and lawful attorney-in-fact
to:
1. complete and execute Forms 3, 4 and 5 and other forms and all amendments
thereto as such attorney-in-fact shall in his discretion determine to be
required or advisable pursuant to Section 16 of the Securities Exchange Act of
1934 (as amended) and the rules and regulations promulgated thereunder, or any
successor laws and regulations, as a consequence of the undersigned's ownership,
acquisition or disposition of securities of the Company; and
2. do all acts necessary in order to file such forms with the SEC, any
securities exchange or national association, the Company and such other person
or agency as the attorneys-in-fact shall deem appropriate.
The undersigned hereby ratifies and confirms all that said attorneys-in-fact and
agents shall do or cause to be done by virtue hereof. The undersigned
acknowledges that the foregoing attorneys-in-fact, in serving in such capacity
at the request of the undersigned, are not assuming, nor is the Company
assuming, any of the undersigned's responsibilities to comply with Section 16 of
the Securities Exchange Act of 1934 (as amended).
This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4 and 5 with respect to the
undersigned's holdings of and transactions in securities issued by the Company,
unless earlier revoked by the undersigned in a signed writing delivered to the
Company and the foregoing attorneys-in-fact.
IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of this 4th day of May, 2021.
Signature: /s/ Winston Kung
Print Name: Winston Kung